Systematic Review with Network Meta-Analysis: Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients

Table 1

Summary matrix showing all pairwise comparisons for treatment response.

AML5	5.21 (2.53, 11.19)	3.93 (2.46, 6.43)	3.37 (1.41, 8.47)	1.97 (0.6, 7.3)	2.74 (1.57, 4.94)	3.29 (1.58, 7.09)	0.26 (0.13, 0.49)
0.19 (0.09, 0.39)	AZL20_AML5	0.75 (0.31, 1.81)	0.65 (0.2, 2.08)	0.38 (0.09, 1.68)	0.53 (0.2, 1.33)	0.63 (0.22, 1.8)	0.05 (0.02, 0.13)
0.25 (0.16, 0.41)	1.33 (0.55, 3.27)	CAN8_AML5	0.86 (0.32, 2.36)	0.5 (0.14, 2.02)	0.7 (0.33, 1.48)	0.84 (0.34, 2.06)	0.07 (0.03, 0.14)
0.3 (0.12, 0.71)	1.55 (0.48, 4.97)	1.17 (0.42, 3.08)	FIM60_AML5	0.59 (0.13, 2.84)	0.82 (0.28, 2.32)	0.98 (0.3, 3.12)	0.08 (0.03, 0.19)
0.51 (0.14, 1.66)	2.64 (0.6, 11.01)	1.99 (0.5, 7.19)	1.7 (0.35, 7.69)	LOS50_AML5	1.39 (0.33, 5.25)	1.66 (0.37, 6.93)	0.13 (0.03, 0.51)
0.36 (0.2, 0.64)	1.9 (0.75, 4.9)	1.43 (0.68, 3.02)	1.22 (0.43, 3.56)	0.72 (0.19, 2.99)	OLM20_AML5	1.2 (0.47, 3.14)	0.09 (0.04, 0.22)
0.3 (0.14, 0.63)	1.59 (0.56, 4.54)	1.19 (0.49, 2.9)	1.02 (0.32, 3.32)	0.6 (0.14, 2.72)	0.84 (0.32, 2.15)	TEL40_AML25	0.08 (0.03, 0.21)
3.82 (2.02, 7.6)	20.1 (7.59, 55.96)	15.04 (7.25, 32.97)	12.91 (5.33, 33.47)	7.61 (1.95, 33.24)	10.54 (4.48, 25.82)	12.63 (4.69, 35.22)	PBO

Abbreviations: AML, amlodipine; AZL, azilsartan; CAN, candesartan; FIM, fimasartan; OLM, olmesartan; TEL, telmisartan; LOS, losartan; PBO, placebo; CI, confidence intervals.